These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 34667027)

  • 21. Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe.
    Davenport C; Gravel P; Wang Y; Williams SA; Wieland A; Mitlak B
    Ther Innov Regul Sci; 2024 May; 58(3):505-518. PubMed ID: 38341388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
    JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory benefit-risk assessment of oncology drugs: A systematic review of FDA and EMA approvals.
    Pinto CA; Balantac Z; Mt-Isa S; Liu X; Bracco OL; Clarke H; Tervonen T
    Drug Discov Today; 2023 Oct; 28(10):103719. PubMed ID: 37467877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021.
    Daval CJR; Teng TW; Russo M; Kesselheim AS
    JAMA Health Forum; 2023 Jul; 4(7):e231718. PubMed ID: 37418270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of Real-World Data and evidence in oncology medicines approved in EU in 2018-2019.
    Eskola SM; Leufkens HGM; Bate A; De Bruin ML; Gardarsdottir H
    J Cancer Policy; 2023 Jun; 36():100424. PubMed ID: 37116794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA Approvals of Oncology Drugs for Tissue-Agnostic Indications.
    Zettler ME
    Target Oncol; 2023 Sep; 18(5):777-792. PubMed ID: 37477750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. US Food and Drug Administration regulatory updates in neuro-oncology.
    Mehta GU; Barone AK; Bradford D; Larkins E; Kim J; Pai-Scherf L; Jaigirdar A; Shah M; Wedam S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA; Singh H
    J Neurooncol; 2021 Jul; 153(3):375-381. PubMed ID: 34156585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020.
    Kim MS; Xu A; Haslam A; Prasad V
    Int J Cancer; 2022 Jun; 150(11):1905-1910. PubMed ID: 35182072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program.
    de Claro RA; Gao JJ; Kim T; Kluetz PG; Theoret MR; Beaver JA; Pazdur R
    Clin Cancer Res; 2021 Jan; 27(1):11-14. PubMed ID: 32816899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of post-marketing requirements for oncology drug conditional approvals in the United States and China.
    Ge C; An J; Chen X
    Heliyon; 2024 Aug; 10(15):e35454. PubMed ID: 39170111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019-2023) by US FDA, best practices and recommendations.
    Mitra A; Lee JB; Steinbach D; Hazra A; Krishna R
    J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):475-493. PubMed ID: 37925369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016.
    Zhou J; Vallejo J; Kluetz P; Pazdur R; Kim T; Keegan P; Farrell A; Beaver JA; Sridhara R
    J Natl Cancer Inst; 2019 May; 111(5):449-458. PubMed ID: 30085269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021.
    Agrawal S; Arora S; Amiri-Kordestani L; de Claro RA; Fashoyin-Aje L; Gormley N; Kim T; Lemery S; Mehta GU; Scott EC; Singh H; Tang S; Theoret MR; Pazdur R; Kluetz PG; Beaver JA
    JAMA Oncol; 2023 Feb; 9(2):266-272. PubMed ID: 36580315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
    J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non-orphan, Non-oncology Drugs in the European Union and United States from 2012-2016.
    Morant AV; Jagalski V; Vestergaard HT
    Clin Transl Sci; 2019 Jul; 12(4):361-370. PubMed ID: 30681284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010.
    Pariser AR; Slack DJ; Bauer LJ; Warner CA; Tracy LA
    Drug Discov Today; 2012 Aug; 17(15-16):898-904. PubMed ID: 22564486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. US FDA's Dose Optimization Postmarketing Requirements and Commitments of Oncology Approvals and the Impact on Product Labels from 2010 to 2022: An Emerging Landscape from Traditional to Novel Therapies.
    Gendy JM; Nomura N; Stuart JN; Blumenthal G
    Ther Innov Regul Sci; 2024 Mar; 58(2):380-386. PubMed ID: 38182940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.